CurrentCardio
Get Weekly

Cardio-oncology & otherCohort study

Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer

CirculationPublished

  • Population-based cohort study
  • inverse probability of treatment and censoring weighting
Read the original article ↗

Authors' conclusion

In this population-based study, aromatase inhibitors were associated with increased risks of heart failure and cardiovascular mortality compared with tamoxifen. There were also trends toward increased risks, although nonsignificant, of myocardial infarction and ischemic stroke.

Study context

Population
Women newly diagnosed with breast cancer initiating hormonal therapy, UK CPRD linked to HES and ONS, 1998–201617,922 initiated treatment
Participants
23,525 women
Exposure
Aromatase inhibitors vs tamoxifen
  • Aromatase inhibitorsn = 8,139
  • Tamoxifenn = 9,783reference
Outcome
MI, ischemic stroke, HF and CV mortality

Main finding

As reported in the abstract

Aromatase inhibitors

5.4 per 1000 person-years

HF · CV mortality 9.5 per 1000 person-years · MI 3.9 per 1000 person-years · Ischemic stroke 5.6 per 1000 person-years

Tamoxifen

1.8 per 1000 person-years

HF · CV mortality 4.7 per 1000 person-years · MI 1.8 per 1000 person-years · Ischemic stroke 3.2 per 1000 person-years

Aromatase inhibitors vs TamoxifenHazard ratio (95% CI)
HF
1.86(1.14–3.03)
CV mortality
1.50(1.11–2.04)
MI
1.37(0.88–2.13)
ischemic stroke
1.19(0.82–1.72)

Observational data: associations, not effects.

Original publication

Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer. Circulation. Published 17 February 2020. doi:10.1161/circulationaha.119.044750
Read the original article ↗PubMedCite RIS · BibTeX

Summarised from the published abstract; every number is checked against it